Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 2.198
1.
Adv Drug Deliv Rev ; 209: 115315, 2024 Jun.
Article En | MEDLINE | ID: mdl-38670230

Immunotherapies have been transformative in many areas, including cancer treatments, allergies, and autoimmune diseases. However, significant challenges persist in extending the reach of these technologies to new indications and patients. Some of the major hurdles include narrow applicability to patient groups, transient efficacy, high cost burdens, poor immunogenicity, and side effects or off-target toxicity that results from lack of disease-specificity and inefficient delivery. Thus, there is a significant need for strategies that control immune responses generated by immunotherapies while targeting infection, cancer, allergy, and autoimmunity. Being the outermost barrier of the body and the first line of host defense, the skin presents a unique immunological interface to achieve these goals. The skin contains a high concentration of specialized immune cells, such as antigen-presenting cells and tissue-resident memory T cells. These cells feature diverse and potent combinations of immune receptors, providing access to cellular and molecular level control to modulate immune responses. Thus, skin provides accessible tissue, cellular, and molecular level controls that can be harnessed to improve immunotherapies. Biomaterial platforms - microneedles, nano- and micro-particles, scaffolds, and other technologies - are uniquely capable of modulating the specialized immunological niche in skin by targeting these distinct biological levels of control. This review highlights recent pre-clinical and clinical advances in biomaterial-based approaches to target and modulate immune signaling in the skin at the tissue, cellular, and molecular levels for immunotherapeutic applications. We begin by discussing skin cytoarchitecture and resident immune cells to establish the biological rationale for skin-targeting immunotherapies. This is followed by a critical presentation of biomaterial-based pre-clinical and clinical studies aimed at controlling the immune response in the skin for immunotherapy and therapeutic vaccine applications in cancer, allergy, and autoimmunity.


Biocompatible Materials , Immunotherapy , Skin , Humans , Immunotherapy/methods , Biocompatible Materials/administration & dosage , Skin/immunology , Skin/metabolism , Animals , Signal Transduction , Drug Delivery Systems
2.
Int J Pharm ; 656: 124099, 2024 May 10.
Article En | MEDLINE | ID: mdl-38614431

Diabetic wounds (DWs) pose a significant health burden worldwide, with their management presenting numerous challenges. Biopolymeric formulations have recently gained attention as promising therapeutic approaches for diabetic wound healing. These formulations, composed of biocompatible and biodegradable polymers, offer unique properties such as controlled drug release, enhanced wound closure, and reduced scarring. In this review, we aim to provide a comprehensive overview of the current state of research and future prospects regarding the application of biopolymeric formulations for diabetic wound healing. The review begins by highlighting the underlying pathophysiology of DWs, including impaired angiogenesis, chronic inflammation, and compromised extracellular matrix (ECM) formation. It further explores the key characteristics of biopolymeric materials, such as their biocompatibility, biodegradability, and tunable physicochemical properties, which make them suitable for diabetic wound healing applications. The discussion further delves into the types of biopolymeric formulations utilized in the treatment of DWs. These include hydrogels, nanoparticles (NP), scaffolds, films, and dressings. Furthermore, the review addresses the challenges associated with biopolymeric formulations for diabetic wound healing. In conclusion, biopolymeric formulations present a promising avenue for diabetic wound healing. Their unique properties and versatility allow for tailored approaches to address the specific challenges associated with DWs. However, further research and developments are required to optimize their therapeutic efficacy, stability, manufacturing processes, and regulatory considerations. With continued advancements in biopolymeric formulations, the future holds great promise for improving the management and outcomes of DWs.


Wound Healing , Wound Healing/drug effects , Humans , Biopolymers/chemistry , Biopolymers/administration & dosage , Animals , Diabetes Mellitus/drug therapy , Hydrogels/chemistry , Hydrogels/administration & dosage , Bandages , Biocompatible Materials/chemistry , Biocompatible Materials/administration & dosage , Nanoparticles/chemistry
3.
Expert Opin Drug Deliv ; 21(4): 573-591, 2024 Apr.
Article En | MEDLINE | ID: mdl-38588553

INTRODUCTION: Endotracheal intubation is a common procedure to maintain an open airway with risks for traumatic injury. Pathological changes resulting from intubation can cause upper airway complications, including vocal fold scarring, laryngotracheal stenosis, and granulomas and present with symptoms such as dysphonia, dysphagia, and dyspnea. Current intubation-related laryngotracheal injury treatment approaches lack standardized guidelines, relying on individual clinician experience, and surgical and medical interventions have limitations and carry risks. AREAS COVERED: The clinical and preclinical therapeutics for wound healing in the upper airway are described. This review discusses the current developments on local drug delivery systems in the upper airway utilizing particle-based delivery systems, including nanoparticles and microparticles, and bulk-based delivery systems, encompassing hydrogels and polymer-based approaches. EXPERT OPINION: Complex laryngotracheal diseases pose challenges for effective treatment, struggling due to the intricate anatomy, limited access, and recurrence. Symptomatic management often requires invasive surgical procedures or medications that are unable to achieve lasting effects. Recent advances in nanotechnology and biocompatible materials provide potential solutions, enabling precise drug delivery, personalization, and extended treatment efficacy. Combining these technologies could lead to groundbreaking treatments for upper airways diseases, significantly improving patients' quality of life. Research and innovation in this field are crucial for further advancements.


Drug Delivery Systems , Wound Healing , Humans , Wound Healing/drug effects , Animals , Intubation, Intratracheal/methods , Quality of Life , Nanoparticles , Hydrogels/administration & dosage , Biocompatible Materials/administration & dosage , Biocompatible Materials/chemistry , Polymers/chemistry , Nanotechnology , Laryngeal Diseases/drug therapy , Trachea/injuries
4.
Eur J Pharm Biopharm ; 199: 114303, 2024 Jun.
Article En | MEDLINE | ID: mdl-38657740

Dissolvable microneedles (DMNs), fabricated from biocompatible materials that dissolve in both water and skin have gained popularity in dermatology. However, limited research exists on their application in compromised skin conditions. This study compares the hyaluronic acid-based DMNs penetration, formation of microchannels, dissolution, and diffusion kinetics in intact, barrier-disrupted (tape stripped), and dry (acetone-treated) porcine ear skin ex vivo. After DMNs application, comprehensive investigations including dermoscopy, stereomicroscope, skin hydration, transepidermal water loss (TEWL), optical coherence tomography (OCT), reflectance confocal laser scanning microscopy (RCLSM), confocal Raman micro-spectroscopy (CRM), two-photon tomography combined with fluorescence lifetime imaging (TPT-FLIM), histology, and scanning electron microscopy (SEM) were conducted. The 400 µm long DMNs successfully penetrated the skin to depths of ≈200 µm for dry skin and ≈200-290 µm for barrier-disrupted skin. Although DMNs fully inserted into all skin conditions, their dissolution rates were high in barrier-disrupted and low in dry skin, as observed through stereomicroscopy and TPT-FLIM. The dissolved polymer exhibited a more significant expansion in barrier-disrupted skin compared to intact skin, with the smallest increase observed in dry skin. Elevated TEWL and reduced skin hydration levels were evident in barrier-disrupted and dry skins compared to intact skin. OCT and RCLSM revealed noticeable skin indentation and pronounced microchannel areas, particularly in barrier-disrupted and dry skin. Additional confirmation of DMN effects on the skin and substance dissolution was obtained through histology, SEM, and CRM techniques. This study highlights the impact of skin condition on DMN effectiveness, emphasizing the importance of considering dissolvability and dissolution rates of needle materials, primarily composed of hyaluronic acid, for optimizing DMN-based drug delivery.


Administration, Cutaneous , Hyaluronic Acid , Needles , Skin Absorption , Skin , Solubility , Animals , Swine , Skin/metabolism , Skin/drug effects , Skin Absorption/drug effects , Skin Absorption/physiology , Hyaluronic Acid/chemistry , Hyaluronic Acid/administration & dosage , Drug Delivery Systems/methods , Tomography, Optical Coherence/methods , Microinjections/methods , Water Loss, Insensible/drug effects , Water Loss, Insensible/physiology , Biocompatible Materials/administration & dosage , Biocompatible Materials/chemistry
5.
J Cosmet Dermatol ; 23(6): 1973-1984, 2024 Jun.
Article En | MEDLINE | ID: mdl-38357772

BACKGROUND: Calcium hydroxylapatite-carboxymethylcellulose (CaHA-CMC) injectables have emerged as dual-purpose fillers with bioregenerative and direct filling capabilities. AIMS: This study investigates the rheological properties of CaHA-CMC and its CMC carrier gel at various dilutions. METHODS: The storage modulus (G'), loss modulus (G″), complex viscosity (η*), loss factor (tan δ), cohesivity, and extrusion force were evaluated for a range of CaHA-CMC aqueous dilutions with an oscillatory rheometer, drop weight testing, and force analysis, respectively. RESULTS: Results revealed a significant decrease in G', η*, and increase in tan(δ) with increasing dilution, indicating a decline in the product's direct filling capabilities. Cohesivity decreased dramatically with dilution, potentially enhancing tissue biointegration and the product's biostimulatory effects. The CMC gel carrier displayed inelastic and non-resilient properties, with rheological changes differing from CaHA-CMC. Dilutional rheology was also correlated with previously published dilution-dependent biostimulatory data where hyperdiluted CaHA-CMC (>1:2) demonstrated a regenerative profile and diluted or hypodiluted mixtures retained meaningful filling properties and increased regeneration. CONCLUSIONS: These findings offer a continuum for tailoring the product's rheological profile to match specific tissue requirements. Customizable rheology allows CaHA-CMC to be tuned for either filling and contouring or optimal regenerative effects. Importantly, safety implications related to vascular occlusion suggest that dilutional rheomodulation decreases the risk of vascular events. In conclusion, this study highlights the significant impact of aqueous dilution on the rheological properties of CaHA-CMC and its carrier gel. The findings support the clinical application of tailored dilutions to achieve desired outcomes, providing versatility and safety for aesthetic applications.


Carboxymethylcellulose Sodium , Dermal Fillers , Durapatite , Rheology , Humans , Carboxymethylcellulose Sodium/chemistry , Carboxymethylcellulose Sodium/administration & dosage , Viscosity , Durapatite/chemistry , Durapatite/administration & dosage , Dermal Fillers/administration & dosage , Dermal Fillers/chemistry , Dermal Fillers/adverse effects , Cosmetic Techniques/instrumentation , Regeneration/drug effects , Gels/chemistry , Materials Testing , Biocompatible Materials/chemistry , Biocompatible Materials/administration & dosage
6.
J Formos Med Assoc ; 123(5): 594-599, 2024 May.
Article En | MEDLINE | ID: mdl-38383169

BACKGROUND/PURPOSE: Biomaterial implants are emerging as a treatment choice for pleurodesis; however, the optimal biomaterial and form for managing spontaneous pneumothorax, particularly post-video-assisted thoracic surgery, remain under investigation. This study evaluated the mechanical and biological properties of the poly-ε-caprolactone (PCL) membrane as a sclerosing agent for pleurodesis in Landrace pigs. METHODS: Twenty-four Landrace pigs were split into two groups for mechanical abrasion and PCL membrane pleurodesis, with the latter group's PCL meshes inserted using video-assisted thoracic surgery. The mechanical and biological properties of the PCL membrane were assessed in pigs at three, six, and 12 months after the procedure. This assessment involved a range of techniques, such as the T-Peel test, macroscopic evaluation with a scoring scale, microscopic examination, and biomechanical and molecular weight analysis. RESULTS: The PCL membrane group outperformed the traditional abrasion group, with stronger adhesions seen over longer implantation durations. This group also showed superior and more consistent results in both macroscopic and microscopic evaluations compared to the control group. The membrane-based method was easier and faster to perform than the control group's method, and importantly, no mortality occurred following membrane implantation. CONCLUSION: This study is the pioneering effort to present long-term findings regarding the mechanical and biological properties of the PCL membrane in an in vivo animal model. The membrane demonstrated better adhesion ability than that of traditional abrasion and showed reassuring biocompatibility in both the pig model, suggesting its potential as treatment for patients with primary spontaneous pneumothorax. Further clinical studies are needed to support these observations.


Biocompatible Materials , Pleurodesis , Polyesters , Animals , Swine , Pleurodesis/methods , Biocompatible Materials/administration & dosage , Pneumothorax/therapy , Thoracic Surgery, Video-Assisted/methods , Membranes, Artificial , Materials Testing , Disease Models, Animal
7.
Nature ; 623(7985): 58-65, 2023 Nov.
Article En | MEDLINE | ID: mdl-37914945

To construct tissue-like prosthetic materials, soft electroactive hydrogels are the best candidate owing to their physiological mechanical modulus, low electrical resistance and bidirectional stimulating and recording capability of electrophysiological signals from biological tissues1,2. Nevertheless, until now, bioelectronic devices for such prostheses have been patch type, which cannot be applied onto rough, narrow or deep tissue surfaces3-5. Here we present an injectable tissue prosthesis with instantaneous bidirectional electrical conduction in the neuromuscular system. The soft and injectable prosthesis is composed of a biocompatible hydrogel with unique phenylborate-mediated multiple crosslinking, such as irreversible yet freely rearrangeable biphenyl bonds and reversible coordinate bonds with conductive gold nanoparticles formed in situ by cross-coupling. Closed-loop robot-assisted rehabilitation by injecting this prosthetic material is successfully demonstrated in the early stage of severe muscle injury in rats, and accelerated tissue repair is achieved in the later stage.


Biocompatible Materials , Hydrogels , Prostheses and Implants , Wounds and Injuries , Animals , Rats , Biocompatible Materials/administration & dosage , Biocompatible Materials/chemistry , Biocompatible Materials/therapeutic use , Electric Conductivity , Gold/chemistry , Hydrogels/administration & dosage , Hydrogels/chemistry , Hydrogels/therapeutic use , Metal Nanoparticles/chemistry , Muscles/injuries , Muscles/innervation , Robotics , Wounds and Injuries/rehabilitation , Wounds and Injuries/surgery
8.
Rev. chil. obstet. ginecol. (En línea) ; 88(2): 95-100, abr. 2023. tab, ilus
Article Es | LILACS | ID: biblio-1441423

OBJETIVO: Presentar una serie de casos de agentes de abultamiento (AA) de nuestro centro. MATERIAL Y MÉTODOS: Estudio retrospectivo. Se evaluaron todos los casos operados con AA entre 2017 y 2022. La inyección de AA se realizó en quirófano, bajo sedación con anestesia local periuretral o raquídea. La inyección se realizó con uretroscopia, 0,5 cc en 4 puntos periuretrales (horas 2, 5, 7 y 10). Se analizaron datos demográficos, quirúrgicos y de seguimiento. RESULTADOS: 15 casos. 13/15 presentaron incontinencia urinaria mixta. Solo dos casos tenían incontinencia de orina de esfuerzo pura. El procedimiento fue ambulatorio. La mediana del tiempo operatorio fue 15 minutos (15-20). La mediana de seguimiento fue 5 meses (1-9). El índice de severidad preoperatorio promedio fue 10,6 y en el seguimiento fue 2,79. La Escala de Mejoría Global mostró mejoría en 12/15, y 12/15 estaban satisfechas con la cirugía con mejoría en la calidad de vida. CONCLUSIÓN: Los AA son una opción quirúrgica efectiva, con una tasa de éxito del 80% en otros reportes, siendo similar con nuestra casuística. Ofrecer esta opción es posible a la hora de hablar de terapias alternativas.


OBJECTIVE: To present a case series of bulking agents (BA) from our center. MATERIAL AND METHODS: Retrospective study. All cases operated with BA between 2017 and 2022 were evaluated. A BA injection was performed in the operating room, under periurethral local anesthesia sedation or spinal anesthesia. The injection was performed with urethroscopy, 0.5 cc in 4 periurethral points (hours 2, 5, 7 and 10). Demographic, surgical, and follow-up data were analyzed. RESULTS: 15 cases were reported. 13/15 patients presented with mixed urinary incontinence. Only 2 cases had pure stress urinary incontinence. The procedure was ambulatory. Median operative time was 15 minutes (15-20). Median follow-up was 5 months (1-9). The average preoperative Sandvik Severity Index was 10.6 and in follow-up was 2.79. The PGI showed improvement in 12/15, and 12/15 were satisfied with the surgery with quality-of-life improvement. CONCLUSION: BA are an effective surgical option, with a success rate of 80%, according to other reports, being similar with our casuistry. Offer this option is possible at the moment of discussing alternative therapies.


Humans , Female , Middle Aged , Urinary Incontinence, Stress/surgery , Biocompatible Materials/administration & dosage , Cross-Sectional Studies , Retrospective Studies , Treatment Outcome , Injections
9.
J Cosmet Dermatol ; 22 Suppl 1: 8-14, 2023 Mar.
Article En | MEDLINE | ID: mdl-36988471

BACKGROUND: Skin aging arises from immunological responses to tissue deterioration and damage. Tissue repair processes encompass the regeneration of original tissue and 'scarless' wound healing seen in foetuses, and the extreme fibrotic responses and scarring seen in adults. Anti-aging aesthetic medicine uses interventions like biomaterial-based fillers to influence these immunological responses and renew aged tissue structure and function. At filler injection sites, an inflammatory response occurs that causes a spectrum of outcomes, ranging from tissue regeneration to fibrosis and filler encapsulation. Importantly, the resulting inflammatory pathway can be predetermined by the biomaterial injected. AIMS: By understanding this immunological process, we can develop Aesthetic Regenerative Scaffolds (ARS) - aesthetic injectable biomaterials - to direct inflammatory wound healing away from chronic, fibrotic responses, and towards physiological tissue regeneration. MATERIALS AND METHODS: We identified and reviewed literature on the immunological and cellular responses to injected dermal fillers, whereby the wound healing response to the injection was moderated under the influence of an injected biomaterial. RESULTS: We described the mechanisms of dermal wound healing and the use of ARS to direct healing towards tissue regeneration instead of scarring. We also summarised studies on extracellular matrix remodeling by calcium hydroxylapatite. We found that Calcium hydroxylapatite fillers produce collagen as they gradually degrade and their spherical structures serve as a scaffold for tissue regeneration. Furthermore, CaHA improved fibroblast contractility, collagen type III and elastin production, proliferation and angiogenesis with less inflammation than hyaluronic acid fillers. DISCUSSION: Regneration pathways can be influenced at specific points between a facial filler biomaterial and the wound healingmechanisms at its site of implantaion. CONCLUSION: Physicians can select scaffolds that direct the immune response away from a fibrotic chronic inflammatory pathway and towards regeneration to enable true repair of the aging skin.


Biocompatible Materials , Cicatrix , Durapatite , Regeneration , Skin Aging , Tissue Scaffolds , Adult , Aged , Humans , Biocompatible Materials/administration & dosage , Biocompatible Materials/adverse effects , Biocompatible Materials/chemistry , Biocompatible Materials/supply & distribution , Cicatrix/etiology , Cicatrix/prevention & control , Collagen/metabolism , Inflammation/physiopathology , Inflammation/prevention & control , Tissue Scaffolds/chemistry , Wound Healing/drug effects , Wound Healing/immunology , Wound Healing/physiology , Skin Aging/immunology , Skin Aging/physiology , Regeneration/immunology , Regeneration/physiology , Extracellular Matrix/drug effects , Extracellular Matrix/immunology , Extracellular Matrix/physiology
10.
Adv Sci (Weinh) ; 9(20): e2200281, 2022 07.
Article En | MEDLINE | ID: mdl-35524641

Emerging evidence indicates that a vicious cycle between inflammation and microthrombosis catalyzes the pathogenesis of inflammatory bowel disease (IBD). Over-stimulated inflammation triggers a coagulation cascade and leads to microthrombosis, which further complicates the injury through tissue hypoxia and ischemia. Herein, an injectable protein hydrogel with anti-thrombosis and anti-inflammation competency is developed to impede this cycle, cross-linked by silver ion mediated metal-ligand coordination and electronic interaction with sulfhydryl functionalized bovine serum albumin and heparin, respectively. The ex vivo experiments show that the hydrogel, HEP-Ag-BSA, exhibits excellent self-healing ability, injectability, biocompatibility, and sustained drug release. HEP-Ag-BSA also demonstrates anti-coagulation and anti-inflammation abilities via coagulation analysis and lipopolysaccharide stimulation assay. The in vivo imaging confirms the longer retention time of HEP-Ag-BSA at inflammatory sites than in normal mucosa owing to electrostatic interactions. The in vivo study applying a mouse model with colitis also reveals that HEP-Ag-BSA can robustly inhibit inflammatory microthrombosis with reduced bleeding risk. This versatile protein hydrogel platform can definitively hinder the "inflammation and microthrombosis" cycle, providing a novel integrated approach against IBD.


Heparin , Hydrogels , Inflammation , Inflammatory Bowel Diseases , Serum Albumin, Bovine , Thrombosis , Animals , Biocompatible Materials/administration & dosage , Biocompatible Materials/therapeutic use , Disease Models, Animal , Drug Liberation , Heparin/administration & dosage , Heparin/therapeutic use , Hydrogels/administration & dosage , Hydrogels/therapeutic use , Inflammation/therapy , Inflammatory Bowel Diseases/therapy , Injections , Mice , Serum Albumin, Bovine/administration & dosage , Serum Albumin, Bovine/therapeutic use , Thrombosis/therapy
11.
Biomed Mater ; 17(2)2022 02 02.
Article En | MEDLINE | ID: mdl-35042195

Due to the avascular characteristic of articular cartilage, its self-repair capacity is limited. When cartilage is damaged or forms osteoarthritis (OA), clinical treatment is necessary. However, conventional treatments, including joint replacement, microfracture, cell and drug therapies, have certain limits. Lately, the exosomes derived from mesenchymal stem cells (MSCs-EXO), which consist of complex transcription factors, proteins and targeting ligand components, have shown great therapeutic potentials. With recent advancements in various biomaterials to extend MSCs-EXO's retention time and control the release propertiesin vivo, biomaterials-assisted exosomes therapy has been soon becoming a practically powerful tool in treating OA. This review analyzes the effects of MSCs-EXO on OA inflammation, metabolism, ageing and apoptosis, and introduces the combinational systems of MSCs-EXO with biomaterials to enhance the repair, anti-inflammatory, and homeostasis regulation functions. Moreover, different types of natural or synthetic biomaterials and their applications with MSCs-EXO were also described and discussed. And finally, we presage the future perspective in the development of biomaterial-assisted exosome therapies, as well as the potential to incorporate with other treatments to enhance their therapeutic effects in OA.


Biocompatible Materials , Exosomes , Osteoarthritis/therapy , Animals , Biocompatible Materials/administration & dosage , Biocompatible Materials/therapeutic use , Cells, Cultured , Humans , Injections, Intra-Articular , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/cytology , Mice , Rats
12.
ACS Appl Mater Interfaces ; 14(3): 3849-3863, 2022 Jan 26.
Article En | MEDLINE | ID: mdl-35019259

Nitric oxide (NO) is an endogenous gasotransmitter regulating alternative physiological processes in the cardiovascular system. To achieve translational application of NO, continued efforts are made on the development of orally active NO prodrugs for long-term treatment of chronic cardiovascular diseases. Herein, immobilization of NO-delivery [Fe2(µ-SCH2CH2COOH)2(NO)4] (DNIC-2) onto MIL-88B, a metal-organic framework (MOF) consisting of biocompatible Fe3+ and 1,4-benzenedicarboxylate (BDC), was performed to prepare a DNIC@MOF microrod for enhanced oral delivery of NO. In simulated gastric fluid, protonation of the BDC linker in DNIC@MOF initiates its transformation into a DNIC@tMOF microrod, which consisted of DNIC-2 well dispersed and confined within the BDC-based framework. Moreover, subsequent deprotonation of the BDC-based framework in DNIC@tMOF under simulated intestinal conditions promotes the release of DNIC-2 and NO. Of importance, this discovery of transformer-like DNIC@MOF provides a parallel insight into its stepwise transformation into DNIC@tMOF in the stomach followed by subsequent conversion into molecular DNIC-2 in the small intestine and release of NO in the bloodstream of mice. In comparison with acid-sensitive DNIC-2, oral administration of DNIC@MOF results in a 2.2-fold increase in the oral bioavailability of NO to 65.7% in mice and an effective reduction of systolic blood pressure (SBP) to a ΔSBP of 60.9 ± 4.7 mmHg in spontaneously hypertensive rats for 12 h.


Biocompatible Materials/pharmacology , Metal-Organic Frameworks/pharmacology , Nitric Oxide/chemistry , Prodrugs/pharmacology , Administration, Oral , Animals , Biocompatible Materials/administration & dosage , Blood Pressure/drug effects , Electrodes , Hydrogen-Ion Concentration , Materials Testing , Metal-Organic Frameworks/administration & dosage , Mice , Nitric Oxide/administration & dosage , Particle Size , Prodrugs/chemistry , Surface Properties
13.
ACS Appl Mater Interfaces ; 14(1): 2058-2070, 2022 Jan 12.
Article En | MEDLINE | ID: mdl-34978415

Oral gene therapy has emerged as a potential optimal treatment for ulcerative colitis (UC). Nucleic acid drugs possessing versatility can not only inhibit inflammation but realize colon mucosal healing, fulfilling the clinical objective of UC therapy. However, the effective accumulation and distribution of oral nucleic acid drugs in the colon remain a considerable challenge. Furthermore, current delivery systems pay more attention to the accumulation of nucleic acid drugs in the colon, while the distribution of nucleic acid drugs in the colon, which plays a key role in the UC treatment, never catches the attention of researchers. Here, we used miR-320 as a model nucleic acid drug to develop a kind of multistage-responsive nanocomplexes (MSNs) based on polymeric nanocapsules and alginate. MSNs possess the pH responsiveness in the stomach, the enzyme responsiveness in the colonic lumen, and the redox responsiveness in the cytoplasm. In vivo imaging results showed that MSNs reach the colon within 2 h and effectively release miR-320 nanocapsules in the colonic lumen. The nanocapsules can further deliver miR-320 to the submucosal layer and even the muscular layer. Moreover, MSNs decreased the activity of myeloperoxidase and proinflammatory cytokines and exhibited anti-inflammatory activity by inhibiting the phosphorylation of IκBα and AKT, reducing colonic inflammation and enhancing mucosal repair. Therefore, MSNs can successfully alleviate UC by improving the accumulation and distribution of oral nucleic acid drugs in the colon, promoting the clinical translational application of nucleic acid drugs in the treatment of UC.


Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Biocompatible Materials/pharmacology , Colitis, Ulcerative/drug therapy , Colon/drug effects , MicroRNAs/pharmacology , Nanoparticles/chemistry , Administration, Oral , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Biocompatible Materials/administration & dosage , Drug Carriers/chemistry , Drug Carriers/pharmacology , Drug Delivery Systems , Humans , Materials Testing , MicroRNAs/administration & dosage , Molecular Structure
14.
ACS Appl Mater Interfaces ; 14(1): 373-382, 2022 Jan 12.
Article En | MEDLINE | ID: mdl-34978423

Postoperative adhesion not only causes severe complications for patients but also increases their economic burden. Injectable bioadhesives with adhesiveness to tissues can cover irregular wounds and stay stable in situ, which is a promising barrier for antiadhesion. However, the potential tissue adhesion caused by bioadhesives' indiscriminate adhesiveness between normal and wounded tissue is still a problem. Herein, by using poly(ethylene glycol) succinimidyl succinate (PEG-SS) and gelatin, a succinyl ester-based bioadhesive (SEgel) was fabricated with self-deactivating properties for postoperative antiadhesion. Because N-hydroxysuccinimide esters (NHS-esters) were used as the adhesive group, the bioadhesives' side in contact with the tissue built covalent anchors quickly to maintain the stability, but the superficial layer facing outward withstood fast hydrolysis and then lost its adhesion within minutes, avoiding the indiscriminate adhesiveness. In addition, because of the specific degradation behavior of succinyl ester, the SEgel with proper in vivo retention was achieved without the worry of causing foreign body reactions and unexpected tissue adhesion. Both the cecum-sidewall adhesion and hepatic adhesion models showed that the SEgel markedly reduced the severity of tissue adhesion. These results, together with the ease of the preparation process and well-proven biocompatibility of raw materials, revealed that the SEgel might be a promising solution for postoperative antiadhesion.


Biocompatible Materials/pharmacology , Esters/pharmacology , Polyethylene Glycols/pharmacology , Succinimides/pharmacology , Tissue Adhesions/drug therapy , Tissue Adhesives/pharmacology , Animals , Biocompatible Materials/administration & dosage , Biocompatible Materials/chemistry , Esters/administration & dosage , Esters/chemistry , Materials Testing , Mice , Molecular Structure , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/chemistry , Succinimides/administration & dosage , Succinimides/chemistry , Tissue Adhesives/administration & dosage , Tissue Adhesives/chemistry
15.
ACS Appl Mater Interfaces ; 14(2): 2587-2596, 2022 Jan 19.
Article En | MEDLINE | ID: mdl-34982524

Inefficient intracellular gene release and transfection limit nonviral gene delivery applications in cancer therapy. Reactive oxygen species (ROS) responsive nonviral gene delivery is the most widely explored strategy for such applications, yet the development of fast and safe ROS responsive nanocarriers proves to be a challenge because of the intracellular chemical equilibrium of high ROS and glutathione levels. Here, we report an ultrasound-enhanced ROS responsive charge-reversal polymeric nanocarrier (BTIL) for fast and efficient pancreatic cancer gene delivery. The BTIL is composed of B-PDEAEA/DNA polyplex-based cores and IR780-loaded liposome coatings. The IR780 is able to produce an excess of ROS under low intensity ultrasound irradiation, thus disequilibrating the chemical equilibrium of ROS and glutathione, and promoting the ROS-responsive positive-to-negative charge-reversal of the B-PDEAEA polymer. This charge conversion results in fast polyplex dissociation and intracellular gene release, inducing efficient gene transfection and cancer cell apoptosis. Moreover, following the intravenous administration, BTIL maintains a stable and long circulation in the bloodstream, achieves orthotopic pancreatic ductal adenocarcinoma distribution, and exhibits potent antitumor activity with negligible side effects. Our results reveal the proposed strategy to be both promising and universal for the development of fast and safe ROS responsive nonviral gene delivery in cancer therapy.


Antineoplastic Agents/pharmacology , Biocompatible Materials/pharmacology , Gene Transfer Techniques , Genetic Therapy , Indoles/pharmacology , Pancreatic Neoplasms/drug therapy , Reactive Oxygen Species/metabolism , Administration, Intravenous , Animals , Antineoplastic Agents/administration & dosage , Apoptosis/drug effects , Biocompatible Materials/administration & dosage , Biocompatible Materials/chemistry , Cell Proliferation/drug effects , Drug Carriers/administration & dosage , Drug Carriers/chemistry , Drug Carriers/pharmacology , Drug Screening Assays, Antitumor , Female , Humans , Indoles/administration & dosage , Materials Testing , Mice , Mice, Nude , Nanoparticles/administration & dosage , Nanoparticles/chemistry , Pancreatic Neoplasms/pathology , Polymers/administration & dosage , Polymers/chemistry , Polymers/pharmacology , Ultrasonic Waves
16.
Nanotechnology ; 33(20)2022 Feb 21.
Article En | MEDLINE | ID: mdl-35090149

In recent years, nanozymes based on two-dimensional (2D) nanomaterials have been receiving great interest for cancer photothermal therapy. 2D materials decorated with nanoparticles (NPs) on their surface are advantageous over conventional NPs and 2D material based systems because of their ability to synergistically improve the unique properties of both NPs and 2D materials. In this work, we report a nanozyme based on flower-like MoS2nanoflakes (NFs) by decorating their flower petals with NCeO2using polyethylenimine (PEI) as a linker molecule. A detailed investigation on toxicity, biocompatibility and degradation behavior of fabricated nanozymes in wild-typeDrosophila melanogastermodel revealed that there were no significant effects on the larval size, morphology, larval length, breadth and no time delay in changing larvae to the third instar stage at 7-10 d for MoS2NFs before and after NCeO2decoration. The muscle contraction and locomotion behavior of third instar larvae exhibited high distance coverage for NCeO2decorated MoS2NFs when compared to bare MoS2NFs and control groups. Notably, the MoS2and NCeO2-PEI-MoS2NFs treated groups at 100µg ml-1covered a distance of 38.2 mm (19.4% increase when compared with control) and 49.88 mm (no change when compared with control), respectively. High-resolution transmission electron microscopy investigations on the new born fly gut showed that the NCeO2decoration improved the degradation rate of MoS2NFs. Hence, nanozymes reported here have huge potential in various fields ranging from biosensing, cancer therapy and theranostics to tissue engineering and the treatment of Alzheimer's disease and retinal therapy.


Biocompatible Materials/toxicity , Cerium/toxicity , Disulfides/toxicity , Molybdenum/toxicity , Nanostructures/toxicity , Animals , Biocompatible Materials/administration & dosage , Biocompatible Materials/chemistry , Biocompatible Materials/pharmacokinetics , Cerium/administration & dosage , Cerium/chemistry , Cerium/pharmacokinetics , Disulfides/administration & dosage , Disulfides/chemistry , Disulfides/pharmacokinetics , Drosophila melanogaster , Gastrointestinal Tract/metabolism , Larva/drug effects , Larva/growth & development , Larva/metabolism , Locomotion/drug effects , Materials Testing , Metabolic Clearance Rate , Molybdenum/administration & dosage , Molybdenum/chemistry , Molybdenum/pharmacokinetics , Muscle Contraction/drug effects , Nanostructures/administration & dosage , Nanostructures/chemistry , Polyethyleneimine/administration & dosage , Polyethyleneimine/chemistry , Polyethyleneimine/pharmacokinetics , Polyethyleneimine/toxicity , Reactive Oxygen Species/metabolism
17.
ACS Appl Mater Interfaces ; 14(1): 259-267, 2022 Jan 12.
Article En | MEDLINE | ID: mdl-34957836

Acute inflammation is a basic innate, immediate, and stereotyped immune response to injury, which is characterized by rapid recruitment of immune cells to the vasculature and extravasation into the damaged parenchyma. Visualization of acute inflammation plays an important role in monitoring the disease course and understanding pathogenesis, which lacks specific targeted and observing tools in vivo. Here, we report a Trojan horse strategy of a macrophage-camouflaged afterglow nanocomplex (UCANPs@RAW) to specifically visualize acute inflammation. Due to the advantages of optical antibackground interference elimination, as well as particular immune homing and long-term tracking capacity, UCANPs@RAW demonstrates an excellent acute inflammatory recognition ability. In an arthritis model, previously intravenously injected UCANPs@RAW could directionally migrate from the liver to the inflammation site as soon as 3 h after the model was induced, which could be continuously lighted for at least 36 h with the highest imaging signal-to-background ratio (SBR) as 382 at the time point of 9 h. Additionally, UCANPs@RAW is observed to penetrate the blood-brain barrier and image the deep brain inflamed region covered by the thick skull in an acute brain inflammation model with an SBRmax of 258, which is based on the strong recruiting ability of macrophages to immune response. In view of this smart nanocomplex, our strategy holds great potential for inflammatory detection and treatments.


Biocompatible Materials/pharmacology , Inflammation/drug therapy , Macrophages/drug effects , Nanoparticles/chemistry , Acute Disease , Animals , Biocompatible Materials/administration & dosage , Biocompatible Materials/chemistry , Disease Models, Animal , Injections, Intravenous , Materials Testing , Mice , Mice, Inbred BALB C , Molecular Structure , Nanoparticles/administration & dosage , Particle Size
18.
ACS Appl Mater Interfaces ; 14(1): 297-306, 2022 Jan 12.
Article En | MEDLINE | ID: mdl-34958191

Aromatized thioketal (ATK) linked the immunoregulatory molecule (budesonide, Bud) and the cytotoxic molecule (gemcitabine, Gem) to construct a ROS-activated Janus-prodrug, termed as BAG. Benefiting from the hydrogen bonding, π-π stacking, and other intermolecular interactions, BAG could self-assemble into nanoaggregates (BAG NA) with a well-defined spherical shape and uniform size distribution. Compared to the carrier-based drug delivery system, BAG NA have ultrahigh drug loading content and ROS concentration-dependent drug release. Colitis-associated colorectal cancer (CAC) is a typical disease in which chronic inflammation transforms into tumors. BAG NA can be internalized by colon cancer C26 cells and then triggered by excessive intracellular ROS to release nearly 100% of the drugs. Based on this, BAG NA showed a stronger pro-apoptotic effect than free Bud combined with free Gem. What is gratifying is that orally administered BAG NA can precisely accumulate in the diseased colon tissues of CAC mice induced by AOM/DSS and simultaneously release Bud and Gem. Bud can regulate the tumor immune microenvironment to restore and enhance the cytotoxicity of Gem. Therefore, BAG NA maximizes the synergistic therapeutic effect through co-delivery of Bud and Gem. This work provided a cutting-edge method for constructing self-delivery Janus-prodrug based on ATK and confirmed its potential application in inflammation-related carcinogenesis.


Antineoplastic Agents/pharmacology , Biocompatible Materials/pharmacology , Colitis-Associated Neoplasms/drug therapy , Colorectal Neoplasms/drug therapy , Drug Delivery Systems , Prodrugs/pharmacology , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/chemistry , Biocompatible Materials/administration & dosage , Biocompatible Materials/chemistry , Budesonide/administration & dosage , Budesonide/chemistry , Budesonide/pharmacology , Cell Line , Colitis-Associated Neoplasms/metabolism , Colitis-Associated Neoplasms/pathology , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Deoxycytidine/chemistry , Deoxycytidine/pharmacology , Materials Testing , Mice , Mice, Inbred BALB C , Molecular Dynamics Simulation , Molecular Structure , Prodrugs/administration & dosage , Prodrugs/chemistry , Gemcitabine
19.
Carbohydr Polym ; 275: 118762, 2022 Jan 01.
Article En | MEDLINE | ID: mdl-34742450

Fungal keratitis remains a serious infectious ocular disease, and the traditional administration of eye drops is limited by ocular intrinsic barriers and drug shortages. Herein, we fabricated a chitosan-based dual-functional platform for ocular topical delivery of econazole. The platform can prolong the residence time on the ocular surface due to its strong interaction with the mucin layer by physical adhesion and covalent bonding, and also open corneal epithelial tight junctions for being positively charged, thereby enhancing corneal penetration of drug. Using these strategies, dosing concentration was reduced from 0.3 wt% to 0.1 wt%, dosing frequency was reduced from once-an-hour to twice-daily, in vitro and in vivo antifungal therapeutic effects were achieved and patient compliance could be improved. Given its high structural adaptability, many other ocular anterior segment-related diseases would benefit from this platform.


Antifungal Agents/pharmacology , Biocompatible Materials/pharmacology , Chitosan/pharmacology , Eye Infections, Fungal/drug therapy , Keratitis/drug therapy , Ophthalmic Solutions/pharmacology , Administration, Ophthalmic , Animals , Antifungal Agents/administration & dosage , Antifungal Agents/chemistry , Biocompatible Materials/administration & dosage , Biocompatible Materials/chemistry , Carbohydrate Conformation , Chitosan/administration & dosage , Chitosan/chemistry , Drug Delivery Systems , Eye Infections, Fungal/microbiology , Female , Fusarium/drug effects , Humans , Keratitis/microbiology , Mice , Mice, Inbred C57BL , Microbial Sensitivity Tests , Ophthalmic Solutions/administration & dosage , Ophthalmic Solutions/chemistry
20.
Mar Drugs ; 19(12)2021 Dec 08.
Article En | MEDLINE | ID: mdl-34940696

Chitosan is one of the most studied natural origin polymers for biomedical applications. This review focuses on the potential of chitosan in localized antimicrobial therapy to address the challenges of current rising antimicrobial resistance. Due to its mucoadhesiveness, chitosan offers the opportunity to prolong the formulation residence time at mucosal sites; its wound healing properties open possibilities to utilize chitosan as wound dressings with multitargeted activities and more. We provide an unbiased overview of the state-of-the-art chitosan-based delivery systems categorized by the administration site, addressing the site-related challenges and evaluating the representative formulations. Specifically, we offer an in-depth analysis of the current challenges of the chitosan-based novel delivery systems for skin and vaginal infections, including its formulations optimizations and limitations. A brief overview of chitosan's potential in treating ocular, buccal and dental, and nasal infections is included. We close the review with remarks on toxicity issues and remaining challenges and perspectives.


Anti-Bacterial Agents/administration & dosage , Biocompatible Materials/administration & dosage , Chitosan , Administration, Cutaneous , Aquatic Organisms , Bandages , Drug Delivery Systems , Humans
...